{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:14:05Z","timestamp":1790766845272,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2021YFC0863400"],"award-info":[{"award-number":["2021YFC0863400"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2022YFE0114700"],"award-info":[{"award-number":["2022YFE0114700"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008551","name":"Fondation M\u00e9rieux","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008551","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biosafety and Health"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.bsheal.2023.08.003","type":"journal-article","created":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T02:16:10Z","timestamp":1693620970000},"page":"272-279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Advances in treatment strategies for COVID-19: Insights from other coronavirus diseases and prospects"],"prefix":"10.1016","volume":"5","author":[{"given":"Yingwen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bsheal.2023.08.003_b0005","unstructured":"World Health Organization, Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. https:\/\/www.who.int\/news\/item\/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern, 2021 (accessed 1 May 2023)."},{"issue":"7798","key":"10.1016\/j.bsheal.2023.08.003_b0010","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"6518","key":"10.1016\/j.bsheal.2023.08.003_b0015","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.abd2985","article-title":"Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity","volume":"370","author":"Cantuti-Castelvetri","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bsheal.2023.08.003_b0020","first-page":"283","article-title":"CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells, Signal Transduct","volume":"5","author":"Wang","year":"2020","journal-title":"Target. Ther."},{"issue":"2","key":"10.1016\/j.bsheal.2023.08.003_b0025","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41422-020-00460-y","article-title":"AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells","volume":"31","author":"Wang","year":"2021","journal-title":"Cell Res."},{"issue":"2","key":"10.1016\/j.bsheal.2023.08.003_b0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bsheal.2023.08.003_b0035","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-020-0184-0","article-title":"The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin","volume":"5","author":"Xia","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bsheal.2023.08.003_b0040","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1038\/s41467-020-19706-9","article-title":"Immune suppression in the early stage of COVID-19 disease","volume":"11","author":"Tian","year":"2020","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bsheal.2023.08.003_b0045","doi-asserted-by":"crossref","first-page":"e2946","DOI":"10.1093\/cid\/ciaa1275","article-title":"Coronavirus disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing","volume":"73","author":"To","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.bsheal.2023.08.003_b0050","doi-asserted-by":"crossref","first-page":"e02769","DOI":"10.1128\/JCM.02769-20","article-title":"The importance and challenges of identifying SARS-CoV-2 reinfections","volume":"59","author":"Babiker","year":"2021","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.bsheal.2023.08.003_b0055","doi-asserted-by":"crossref","unstructured":"World Health Organization, Update to living WHO guideline on drugs for covid-19, BMJ 374 (2021) n2219, https:\/\/doi.org\/10.1136\/bmj.n2219.","DOI":"10.1136\/bmj.n2219"},{"issue":"19","key":"10.1016\/j.bsheal.2023.08.003_b0060","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - Final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bsheal.2023.08.003_b0065","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","article-title":"Nirmatrelvir plus ritonavir: First approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bsheal.2023.08.003_b0070","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","article-title":"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis","volume":"54","author":"Wen","year":"2022","journal-title":"Ann. Med."},{"issue":"8","key":"10.1016\/j.bsheal.2023.08.003_b0075","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with Covid-19","volume":"384","author":"Group","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bsheal.2023.08.003_b0080","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S2213-2600(20)30328-3","article-title":"Groupe de Recherche Clinique en, E.-C.i. Paris-Sorbonne, Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study","volume":"8","author":"Schmidt","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"10257","key":"10.1016\/j.bsheal.2023.08.003_b0085","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0140-6736(20)32008-0","article-title":"O. Extracorporeal Life Support, Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry","volume":"396","author":"Barbaro","year":"2020","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.bsheal.2023.08.003_b0090","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"J. Am. Med. Assoc."},{"issue":"5","key":"10.1016\/j.bsheal.2023.08.003_b0095","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial","volume":"324","author":"Li","year":"2020","journal-title":"J. Am. Med. Assoc."},{"issue":"7520","key":"10.1016\/j.bsheal.2023.08.003_b0100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.bsheal.2023.08.003_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030237","article-title":"Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants","volume":"3","author":"ter Meulen","year":"2006","journal-title":"PLoS Med."},{"issue":"5","key":"10.1016\/j.bsheal.2023.08.003_b0110","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/jmv.27542","article-title":"Bamlanivimab plus etesevimab treatment have a better outcome against COVID-19: A meta-analysis","volume":"94","author":"Xiang","year":"2022","journal-title":"J. Med. Virol."},{"issue":"10325","key":"10.1016\/j.bsheal.2023.08.003_b0115","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","author":"Group","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bsheal.2023.08.003_b0120","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s40121-021-00515-6","article-title":"A narrative review of the clinical practicalities of bamlanivimab and etesevimab antibody therapies for SARS-CoV-2","volume":"10","author":"Nathan","year":"2021","journal-title":"Infect. Dis. Ther."},{"issue":"6506","key":"10.1016\/j.bsheal.2023.08.003_b0125","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bsheal.2023.08.003_b0130","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bsheal.2023.08.003_b0135","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jama.2021.8828","article-title":"Investigators, Effect of bamlanivimab vs placebo on iof COVID-19 among residents and staff of skilled nursing and assisted living facilities: A Randomized clinical trial","volume":"326","author":"Cohen","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.bsheal.2023.08.003_b0140","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3390\/v13091850","article-title":"Efficient inhibition of HIV using CRISPR\/Cas13d nuclease system","volume":"13","author":"Nguyen","year":"2021","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.bsheal.2023.08.003_b0145","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/s41587-020-0513-4","article-title":"CRISPR-Cas12-based detection of SARS-CoV-2","volume":"38","author":"Broughton","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.bsheal.2023.08.003_b0150","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1021\/acssynbio.1c00499","article-title":"Bio-SCAN: A CRISPR\/dCas9-based lateral flow assay for rapid, specific, and sensitive detection of SARS-CoV-2","volume":"11","author":"Ali","year":"2022","journal-title":"A.C.S. Synth. Biol."},{"issue":"2","key":"10.1016\/j.bsheal.2023.08.003_b0155","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.cell.2020.12.001","article-title":"Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy","volume":"184","author":"Fozouni","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bsheal.2023.08.003_b0160","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12033-022-00567-0","article-title":"A review on the mechanism and applications of CRISPR\/Cas9\/Cas12\/Cas13\/Cas14 proteins utilized for genome engineering","volume":"65","author":"Hillary","year":"2023","journal-title":"Mol. Biotechnol."},{"issue":"4","key":"10.1016\/j.bsheal.2023.08.003_b0165","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2020.04.020","article-title":"Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza","volume":"181","author":"Abbott","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bsheal.2023.08.003_b0170","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"10","key":"10.1016\/j.bsheal.2023.08.003_b0175","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41589-022-01094-4","article-title":"Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection","volume":"18","author":"Cui","year":"2022","journal-title":"Nat. Chem. Biol."},{"issue":"6","key":"10.1016\/j.bsheal.2023.08.003_b0180","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.bsheal.2023.08.003_b0185","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00766-18","article-title":"Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses","volume":"62","author":"Yoon","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.bsheal.2023.08.003_b0190","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/infdis\/jiab361","article-title":"Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants of concern in a hamster infection model","volume":"224","author":"Abdelnabi","year":"2021","journal-title":"J. Infect. Dis."},{"issue":"24","key":"10.1016\/j.bsheal.2023.08.003_b0195","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01348-19","article-title":"et al., Small-molecule antiviral beta-d-N(4)-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance","volume":"93","author":"Agostini","year":"2019","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.bsheal.2023.08.003_b0200","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bsheal.2023.08.003_b0205","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus Remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bsheal.2023.08.003_b0210","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"8","key":"10.1016\/j.bsheal.2023.08.003_b0215","article-title":"Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients, E.M.B.O","volume":"12","author":"Stebbing","year":"2020","journal-title":"Mol. Med."},{"issue":"2","key":"10.1016\/j.bsheal.2023.08.003_b0220","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.cell.2020.11.007","article-title":"Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques","volume":"184","author":"Hoang","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.bsheal.2023.08.003_b0225","doi-asserted-by":"crossref","first-page":"103255","DOI":"10.1016\/j.ebiom.2021.103255","article-title":"Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite G.B.P.A. exerts antiviral activity","volume":"65","author":"Hoffmann","year":"2021","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.bsheal.2023.08.003_b0230","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/bcpt.13533","article-title":"et al., Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety","volume":"128","author":"Breining","year":"2021","journal-title":"Basic Clin. Paharmacol. Toxicol."},{"issue":"6","key":"10.1016\/j.bsheal.2023.08.003_b0235","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2213-2600(20)30216-2","article-title":"COVID-19 cytokine storm: the interplay between inflammation and coagulation","volume":"8","author":"Jose","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.bsheal.2023.08.003_b0240","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41577-020-0308-3","article-title":"COVID-19: immunopathology and its implications for therapy","volume":"20","author":"Cao","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"10236","key":"10.1016\/j.bsheal.2023.08.003_b0245","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bsheal.2023.08.003_b0250","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41392-021-00860-5","article-title":"Female sex hormone, progesterone, ameliorates the severity of SARS-CoV-2-caused pneumonia in the Syrian hamster model","volume":"7","author":"Yuan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.bsheal.2023.08.003_b0255","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41423-021-00793-7","article-title":"Dexamethasone ameliorates severe pneumonia but slightly enhances viral replication in the lungs of SARS-CoV-2-infected Syrian hamsters","volume":"19","author":"Yuan","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bsheal.2023.08.003_b0260","doi-asserted-by":"crossref","unstructured":"P. Mehta, D.F. McAuley, M. Brown, E. Sanchez, R.S. Tattersall, J.J. Manson, U.K. Hlh Across Speciality Collaboration, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet 395(10229) (2020) 1033-1034, https:\/\/doi.org\/10.1016\/S0140-6736(20)30628-0.","DOI":"10.1016\/S0140-6736(20)30628-0"},{"issue":"1","key":"10.1016\/j.bsheal.2023.08.003_b0265","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","article-title":"A guide to immunotherapy for COVID-19","volume":"28","author":"van de Veerdonk","year":"2022","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bsheal.2023.08.003_b0270","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/jmv.26232","article-title":"The cytokine storm and COVID-19","volume":"93","author":"Hu","year":"2021","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.bsheal.2023.08.003_b0275","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2020.06.017","article-title":"Cytokine storms: Understanding COVID-19","volume":"53","author":"Mangalmurti","year":"2020","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.bsheal.2023.08.003_b0280","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.2117","article-title":"A phase II clinical trial of low-dose tocilizumab in the treatment of noncritical COVID-19 pneumonia","volume":"109","author":"Strohbehn","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.bsheal.2023.08.003_b0285","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/cpt.1931","article-title":"Applied clinical pharmacology in a crisis: Interleukin-6 axis blockade and COVID-19","volume":"108","author":"Strohbehn","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bsheal.2023.08.003_b0290","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12879-020-05730-z","article-title":"JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis","volume":"21","author":"Walz","year":"2021","journal-title":"B.M.C. Infect. Dis."},{"issue":"6","key":"10.1016\/j.bsheal.2023.08.003_b0295","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/nsr\/nwaa041","article-title":"Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients","volume":"7","author":"Zhou","year":"2020","journal-title":"Natl. Sci. Rev."},{"issue":"1","key":"10.1016\/j.bsheal.2023.08.003_b0300","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41467-021-21907-9","article-title":"Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications","volume":"12","author":"Xiao","year":"2021","journal-title":"Nat. Commun."},{"issue":"24","key":"10.1016\/j.bsheal.2023.08.003_b0305","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with Covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bsheal.2023.08.003_b0310","first-page":"1918","article-title":"A review pertaining to SARS-CoV-2 and autoimmune diseases: What is the connection?","volume":"12","author":"Kocivnik","year":"2022","journal-title":"Life (Basel)"},{"issue":"10","key":"10.1016\/j.bsheal.2023.08.003_b0315","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202000954","article-title":"Integrated human\/SARS-CoV-2 metabolic models present novel treatment strategies against COVID-19","volume":"4","author":"Bannerman","year":"2021","journal-title":"Life Sci Alliance"},{"issue":"6","key":"10.1016\/j.bsheal.2023.08.003_b0320","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41434-020-00209-7","article-title":"Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics","volume":"28","author":"Berber","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.bsheal.2023.08.003_b0325","first-page":"2414","article-title":"Advances of CRISPR-Cas13 system in COVID-19 diagnosis and treatment","author":"Zhou","year":"2022","journal-title":"Genes Dis."},{"issue":"5","key":"10.1016\/j.bsheal.2023.08.003_b0330","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41422-021-00476-y","article-title":"Predicting dynamic cellular protein-RNA interactions by deep learning using In vivo RNA structures","volume":"31","author":"Sun","year":"2021","journal-title":"Cell Res."},{"issue":"7","key":"10.1016\/j.bsheal.2023.08.003_b0335","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.cell.2021.02.008","article-title":"In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs","volume":"184","author":"Sun","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.bsheal.2023.08.003_b0340","doi-asserted-by":"crossref","unstructured":"R.J. Andrews, W.B. Rouse, C.A. O\u2019Leary, N.J. Booher, W.N. Moss, ScanFold 2.0: a rapid approach for identifying potential structured RNA targets in genomes and transcriptomes, PeerJ 10 (2022) e14361, https:\/\/doi.org\/10.7717\/peerj.14361.","DOI":"10.7717\/peerj.14361"},{"issue":"3","key":"10.1016\/j.bsheal.2023.08.003_b0345","doi-asserted-by":"crossref","first-page":"bbac147","DOI":"10.1093\/bib\/bbac147","article-title":"D3AI-CoV: a deep learning platform for predicting drug targets and for virtual screening against COVID-19","volume":"23","author":"Yang","year":"2022","journal-title":"Brief. Bioinform."},{"issue":"1","key":"10.1016\/j.bsheal.2023.08.003_b0350","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41422-022-00727-6","article-title":"Deep learning-based rapid generation of broadly reactive antibodies against SARS-CoV-2 and its Omicron variant","volume":"33","author":"Lou","year":"2023","journal-title":"Cell Res."}],"container-title":["Biosafety and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590053623001052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590053623001052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:47:22Z","timestamp":1778906842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590053623001052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2590053623001052"],"URL":"https:\/\/doi.org\/10.1016\/j.bsheal.2023.08.003","relation":{},"ISSN":["2590-0536"],"issn-type":[{"value":"2590-0536","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in treatment strategies for COVID-19: Insights from other coronavirus diseases and prospects","name":"articletitle","label":"Article Title"},{"value":"Biosafety and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bsheal.2023.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Chinese Medical Association Publishing House. Published by Elsevier BV.","name":"copyright","label":"Copyright"}]}}